Harry P. Erba, MD, PhD
Accepting New Patients
Duke Health Provider question
I strive to gain the trust of each of my patients, so that I can help them make difficult treatment decisions.
– Harry P. Erba, MD, PhD

Harry P. Erba, MD, PhD

Hematologic Oncologist, Hematologist (Malignant)

Duke Health Provider question
Accepting New Patients
Call for an Appointment
Areas of Expertise
Where I See Patients
Duke Blood Cancer Center - Durham, NC
Duke Cancer Center - Durham, NC
Duke Hematologic Malignancies Clinic - Durham, NC
Board Certified
American Board of Internal Med, Hematology
I strive to gain the trust of each of my patients, so that I can help them make difficult treatment decisions.
– Harry P. Erba, MD, PhD

About Me

I entered medical school for the sole purpose of learning more about human diseases, so that I could focus my laboratory efforts on improving the human condition. However, I was surprised to find myself drawn to clinical care. I care for people afflicted by acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. In this role, I have had the privilege of treating people facing life-threatening illnesses. I strive to gain the trust of each of my patients, so that I can help them make difficult treatment decisions. I engage in clinical research, evaluating novel agents that directly target the cancer cell to improve the degree of success in treating this illness. My patients benefit from my understanding of the newest available treatments, and also have access to promising investigational agents, when appropriate. In my faculty position at Duke University, I enjoy educating current oncologists as well as the next generation of physicians.

Current Appointments and Affiliations
Languages I Speak

Call for an Appointment

Areas of Expertise

  • Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Hairy Cell Leukemia
  • Myelodysplastic Syndrome
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Myeloproliferative Neoplasms

Ratings and Reviews

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more about our survey process. Responses are measured on a scale of 1 to 5 with 5 being the best score. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.

Overall Provider Rating
4.95 out of 5
223 ratings, 35 reviews

Training and Education

Board Certification
American Board of Internal Med, Hematology
Hematology-Oncology, Harvard Medical School, Brigham & Women's Hospital (Massachusetts), 1990-1993
Internal Medicine, Brigham and Women's Hospital (Massachusetts), 1988-1990
MD, Stanford University School of Medicine (California), 1988

Clinical Focus and Research

My Research Interests

I treat people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). In general, therapies initially developed for these cancers were drugs that killed cells that are dividing. Unfortunately, many normal cells in the body are also affected or killed by these drugs as well, leading to the unwanted toxicities of chemotherapy. Over the years, we have gained tremendous insight into the specific events that cause a cell to become cancerous and have developed better tools for distinguishing normal from cancerous cells. My clinical research effort for over 20 years has focused on the development of drugs that specifically target the abnormalities of the leukemia cell. I study the effects associated with treating people with investigational agents that target the molecular changes that are specific to blood cancers. I have been an active member of teams of doctors that have brought new treatments to people with leukemia, such as oral drugs that inactivate FLT3 and IDH. In this way we hope to improve the outcome of people with blood cancers with fewer unwanted side effects.

Clinical Trials
Publications and Grants

Insurance Accepted

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.

    • Aetna Choice POS, Aetna Choice POS II
    • Aetna Elect Choice HMO, Aetna Open Access Elect Choice
    • Aetna Health Network Only, Aetna Health Network Option
    • Aetna HMO
    • Aetna Limited Benefit Insurance PPO
    • Aetna Managed Choice POS
    • Aetna Medicare Assure Plan (HMO D-SNP)
    • Aetna Medicare Eagle Plan (PPO)
    • Aetna Medicare Essential Plan (PPO)
    • Aetna Medicare Value Plan (HMO)
    • Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
    • Aetna Open Choice PPO
    • Aetna PCP Coordinated POS Plan
    • Aetna Quality Point of Service (QPOS)
    • Aetna Select HMO
    • Aetna Traditional Choice
    • Aetna Voluntary Indemnity Group Plan
    • Aetna Whole Health – Duke WakeMed WKCC
    • Aetna/CVS Health
    • Ambetter of North Carolina
    • Blue Advantage
    • Blue Medicare (HMO, PPO)*
    • Blue Options (123, PPO, HSA)
    • Blue Select
    • NC State Employees Health Plan
    • *Duke HomeCare and Hospice does not participate in the plan.

    • Cigna Behavioral Health (*Limited eligibility)
    • Cigna Choice Plus
    • Cigna Connect Individual Family Plan
    • Cigna Open Access
    • Cigna Open Access Plus
    • *Please call Cigna Behavioral Heath to see if the provider is participating in your plan.

    • Duke Basic
    • Duke Select
    • Experience Health Medicare Advantage (HMO) Plan
  • Gateway Health Alliance
  • Healthgram
    • Humana Choice (PPO)
    • Humana Choice - Medicare Advantage (PPO)
    • Humana ChoiceCare - Medicare Advantage (PPO)
    • Humana Gold Choice - Medicare Advantage (PFFS)
    • Humana Gold Plus - Medicare Advantage (HMO)
    • Humana Medicare Advantage Group Plan - NC State Retirees
  • MedCost
    • First Medicare Direct
    • Medicare Part A
    • Medicare Part B
    • AmeriHealth Caritas North Carolina
    • Carolina Complete Health
    • Healthy Blue
    • NC Medicaid Direct
    • WellCare of North Carolina
    • TRICARE Prime
    • TRICARE Prime Remote
    • TRICARE Select
    • AARP Medicare Advantage Plan 2 (HMO-POS)
    • AARP Medicare Complete (HMO, PPO)*
    • AARP Medicare Complete Essential (HMO)*
    • All Savers Alternate Funding
    • All Savers Fully Insured
    • United Healthcare (HMO, PPO, POS)
    • United Healthcare Charter/Charter Balance/Charter Plus
    • United Healthcare Choice/Choice Plus
    • United Healthcare Core/Core Essential
    • United Healthcare Navigate/Navigate Plus/Navigate Balanced
    • United Healthcare Option PPO
    • United Healthcare Passport Connect Choice/Choice Plus
    • United Healthcare Passport Connect Options PPO
    • United Healthcare Select/Select Plus
    • United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
    • United Medical Resources (UMR)
    • *Duke HomeCare and Hospice and mental health providers do not participate with the plan.

Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.

External Relationships

This faculty member (or a member of their immediate family) has reported outside activities with the companies or institutions listed below. This information has been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts of interest.
  • AbbVie, Inc.
  • Astellas Pharma Inc.
  • Astra Zeneca
  • Bristol-Myers Squibb
  • Daiichi Sankyo Co., Ltd
  • Glycomimetics
  • Incyte
  • Jazz Pharmaceuticals
  • Kura Oncology
  • Pfizer
  • Schrodinger
  • Servier
  • Stemline Therapeutics, Inc.
  • Sumitomo Dainippon Pharma Oncology